Atea Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update
Atea Pharmaceuticals, Inc. (AVIR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Atea Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update Phase 3 C-BEYOND Trial Achieved Primary and Secondary Endpoints, Reinforcing Potential Best-in-Class Profile of BEM/RZR for Treatment of Hepatitis C Virus (HCV) Infection P
How this was made
The 30-second read
Why it matters
The Phase 3 results provide a clear catalyst for AVIR, likely prompting analyst upgrades and price appreciation ahead of a potential NDA filing.
Market read
Primary biotech news with immediate price impact; sector‑wide relevance modest.
What to watch
Potential competition from other pan‑genotypic regimens and reimbursement uncertainties.
Atea reports Q3 2026 net loss of $(32,162) thousand as C-BEYOND Phase 3 met its endpoints and a credit facility of up to $200 million with Hercules Capital was signed
The filing reports positive Phase 3 topline results for BEM/RZR and a lower quarterly operating expense base, but the company still reports a GAAP net loss, no revenue line, cash and investments down from $301.8 million at December 31, 2025 to $191.2 million at September 30, 2026, and new borrowings under the Hercules facility.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Research and development expenses, three months ended September 30, 2026GAAP | $27.09M | – | decreased by $11.3 million |
| Research and development expenses, nine months ended September 30, 2026GAAP | $96.38M | – | – |
| General and administrative expenses, three months ended September 30, 2026GAAP | $6.92M | – | decreased by $0.3 million |
| General and administrative expenses, nine months ended September 30, 2026GAAP | $20.75M | – | – |
| Total operating expenses, three months ended September 30, 2026GAAP | $34.01M | – | – |
| Total operating expenses, nine months ended September 30, 2026GAAP | $117.1M | – | – |
| Loss from operations, three months ended September 30, 2026GAAP | −$34.01M | – | – |
| Loss from operations, nine months ended September 30, 2026GAAP | −$117.1M | – | – |
| Interest income and other, net, three months ended September 30, 2026GAAP | $1.89M | – | decreased by $1.8 million |
| Interest income and other, net, nine months ended September 30, 2026GAAP | $6.70M | – | – |
| Loss before income taxes, three months ended September 30, 2026GAAP | −$32.12M | – | – |
| Loss before income taxes, nine months ended September 30, 2026GAAP | −$110.4M | – | – |
| Income tax expense, three months ended September 30, 2026GAAP | −$38K | – | – |
| Income tax expense, nine months ended September 30, 2026GAAP | −$112K | – | – |
| Net loss, three months ended September 30, 2026GAAP | −$32.16M | – | – |
| Net loss, nine months ended September 30, 2026GAAP | −$110.5M | – | – |
| Comprehensive loss, three months ended September 30, 2026GAAP | −$32.14M | – | – |
| Comprehensive loss, nine months ended September 30, 2026GAAP | −$110.8M | – | – |
| Net loss per share, basic and diluted, three months ended September 30, 2026GAAP | $(0.40) | – | – |
| Net loss per share, basic and diluted, nine months ended September 30, 2026GAAP | $(1.38) | – | – |
| Cash, cash equivalents and marketable securities at September 30, 2026GAAP | $191.2M | – | – |
Capital returns
- No share repurchases or dividends are reported in the filing.
- The filing reports no capital return figures.
What drove it
- R&D decrease: the company states the net decrease was primarily driven by a decrease in external spend for the HCV Phase 3 clinical development, offset by an increase in external spend for HEV preclinical and clinical development activities.
- R&D decrease: the company also cites lower internal R&D expenses, which it states were primarily related to lower stock-based compensation expense in the three months ended September 30, 2026.
- G&A decrease: the company states the net decrease was primarily related to lower stock-based compensation expense.
- Interest income and other, net decrease: the company states it was primarily due to lower investment balances.
- Income tax expense: the company reports $0.1 million and $0.2 million for the three months ended September 30, 2026 and 2025, respectively.
Concerns
- Atea reports a GAAP net loss in every period presented, with net loss of $(32,162) thousand for the quarter and $(110,535) thousand for the nine months ended September 30, 2026.
- No revenue line is presented in the filing.
- Cash, cash equivalents and marketable securities declined from $301,830 thousand at December 31, 2025 to $191,199 thousand at September 30, 2026.
- The company drew $65 million under the Hercules Capital facility at closing on November 6, 2026, adding debt to the balance sheet.
- The release describes the Hercules facility's additional $135 million as subject to milestones and other conditions, and the stated runway into mid-2028 is tied to the current operating plan.
- The release notes that risks related to the company's outstanding debt and its ability to manufacture sufficient commercial product are among the forward-looking risk factors.
- The release identifies competition from approved HCV treatments and dependence on BEM/RZR as key risk factors.
What to watch
- C-FORWARD Phase 3 topline results, anticipated in early 2027, and the company's stated expectation that they will show efficacy across a broad range of HCV genotypes.
- NDA submission to the FDA for BEM/RZR, targeted for mid-2027.
- Initiation of the AT-587 HEV proof-of-concept study, anticipated in the first half of 2027.
- Achievement of milestones that would give Atea access to up to $135 million of additional borrowings under the Hercules facility.
- Quarterly cash, cash equivalents and marketable securities balances against the company's stated runway into mid-2028.
- R&D spend mix between the HCV Phase 3 program and HEV development, as the company describes its external spend shifting between the two.
Balance sheet and cash flow
- Cash, cash equivalents and marketable securities: $191.2 million at September 30, 2026 compared to $301.8 million at December 31, 2025 (table: $191,199 thousand and $301,830 thousand).
- Total assets: $200,706 thousand at September 30, 2026 compared to $315,218 thousand at December 31, 2025.
- Total liabilities: $25,025 thousand at September 30, 2026 compared to $39,784 thousand at December 31, 2025.
- Total stockholder's equity: $175,681 thousand at September 30, 2026 compared to $275,434 thousand at December 31, 2025.
- Working capital (company definition: current assets less current liabilities): $175,243 thousand at September 30, 2026 compared to $271,207 thousand at December 31, 2025.
- Hercules Capital credit facility: up to $200 million, signed November 9, 2026. Atea drew down $65 million at closing on November 6, 2026.
- Additional borrowings: up to $135 million, accessible at Atea's option subject to achievement of specified milestones and other terms of the loan agreement.
- Company statement: current resources, based on its current operating plan together with current cash, cash equivalents and investments, are anticipated to fund planned operations into mid-2028.
- Company statement: additional borrowings could extend the cash runway potentially to profitability, assuming a successful commercial launch of BEM/RZR in the US and future expenditures consistent with the current operating plan.
- Operating cash flow and free cash flow are not reported in the filing.
Analysis
Atea's third quarter 2026 release is primarily a clinical update with a condensed statement of operations. The company reports a net loss of $(32,162) thousand for the three months ended September 30, 2026, compared with $(42,049) thousand for the same quarter of 2025, and a net loss of $(110,535) thousand for the nine months ended September 30, 2026, compared with $(113,482) thousand a year earlier. Basic and diluted net loss per share is $(0.40) for the quarter, against $(0.53) in the prior-year quarter. No revenue, gross margin or product sales line appears in the filing, which is consistent with the company being described as a late-stage clinical company.
Operating expenses fell in the quarter. Research and development expenses were $27,091 thousand, down from $38,347 thousand, a decrease the release describes as $11.3 million. General and administrative expenses were $6,922 thousand, against $7,220 thousand. Total operating expenses were $34,013 thousand compared with $45,567 thousand. The company attributes the R&D decline primarily to lower external spend on the HCV Phase 3 program, partly offset by higher external spend on HEV development, and attributes both expense declines in part to lower stock-based compensation. Interest income and other, net fell to $1,889 thousand from $3,714 thousand, which the company links to lower investment balances.
The balance sheet shows the cost of this development program in cash terms. Cash, cash equivalents and marketable securities were $191,199 thousand at September 30, 2026, against $301,830 thousand at December 31, 2025. Total assets were $200,706 thousand and total stockholder's equity was $175,681 thousand at the quarter end. The company signed a credit facility with Hercules Capital for up to $200 million on November 9, 2026, and drew $65 million at closing on November 6, 2026. The release states that up to $135 million of further borrowings may be accessed at Atea's option subject to milestones, and that current resources are anticipated to fund planned operations into mid-2028. The filing does not report operating or free cash flow for the period, so the cash consumption rate cannot be read directly from the release.
Clinically, the filing's main content is the C-BEYOND Phase 3 result. The mITT primary analysis reported a 93.91% SVR rate for BEM/RZR against 94.75% for SOF/VEL (Epclusa) at Week 24, and the company states that non-inferiority was met on the primary and secondary endpoints. C-FORWARD is fully enrolled with more than 880 patients across 17 countries, with topline results expected in early 2027, and an NDA submission is targeted for mid-2027. The HEV program has completed the single ascending dose portion of its Phase 1 study for AT-587, with a proof-of-concept study anticipated in the first half of 2027.
The central question for a reader is the balance between a regulatory and clinical path that the company describes as advancing on schedule and a financial position that now includes drawn debt and a declining cash balance. The release does not provide a forecast, guidance or consensus comparison, so the assessment rests on the reported results and stated timelines. The company's own statement that profitability could be reached only with a successful US launch of BEM/RZR, if approved, is the point the release itself links the new facility to.
Management, verbatim
The C-BEYOND results are strong and reinforce our conviction that the regimen of BEM/RZR will deliver a differentiated profile, including high HCV cure rates, short treatment duration, a low risk of drug-drug interactions and no food effect, which we believe are critical to drive broad adoption of BEM/RZR in clinical practice by prescribers,
Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder
We anticipate the upcoming topline Phase 3 results of C-FORWARD should further validate the potential of BEM/RZR, if approved, to be a new pan-genotypic treatment option for prescribers to treat people living with HCV,
Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder
Not in the filing
stated, not guessed- Total revenue or any revenue line: not reported in the filing.
- Gross margin and cost of sales: not reported.
- Segment or geographic revenue breakdown: not reported.
- Prior-quarter (Q2 2026) figures for any line item: not printed in the filing.
- Year-over-year change figures for the nine-month columns, and for net loss, comprehensive loss, loss from operations, loss before income taxes, income tax expense and EPS: not printed as changes in the filing.
- Prior-year comparison for the cash, cash equivalents and marketable securities balance: the filing compares it with December 31, 2025, not with the prior-year quarter.
- Operating cash flow and free cash flow: not reported.
- Financial guidance for revenue, operating expenses or any other metric: not provided.
- Prior-period outlook: not provided, so no guidance comparison is possible.
- Capital returns (share repurchases, dividends): not reported.
- Total debt outstanding at September 30, 2026: not printed (the Hercules draw of $65 million occurred on November 6, 2026, after the balance sheet date).
- Share price reaction and analyst consensus: not in the documents.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Atea Pharmaceuticals (NASDAQ: AVIR) is a late‑stage biotech focused on oral antivirals for viral hepatitis. The company also disclosed a $200 M credit facility with Hercules Capital.
Ticker impact
Atea Pharmaceuticals filed an 8‑K reporting positive Phase 3 C‑BEYOND trial results that met primary and secondary endpoints for its HCV regimen.
upward pressure as investors price in potential FDA approval and market launch.
First disclosure of statistically significant Phase 3 results for a late‑stage antiviral; material clinical milestone for a small‑cap biotech.
Market effects
Strengthens the HCV antiviral pipeline narrative, may boost peer biotech valuations.
US biotech sector could see modest gains on the news.
Limited to healthcare investors; no broad market effect.
Counterpoint
If the trial data fails to translate into regulatory approval or commercial uptake, the rally could be short‑lived.
Key entities
- companyAtea Pharmaceuticals
NASDAQ‑listed biotech reporting trial data and financing.
- financial_institutionHercules Capital
Provider of a $200 M credit facility to Atea.
